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Abstract
Although the induction of senescence in cancer cells is a potent mechanism of tumor suppression, senescent
cells remain metabolically active and may secrete a broad spectrum of factors that promote tumorigenicity in
neighboring malignant cells. Here we show that androgen deprivation therapy (ADT), a widely used treatment
for advanced prostate cancer, induces a senescence-associated secretory phenotype in prostate cancer epithelial
cells, indicated by increases in senescence-associated β-galactosidase activity, heterochromatin protein 1β foci,
and expression of cathepsin B and insulin-like growth factor binding protein 3. Interestingly, ADT also induced high
levels of vimentin expression in prostate cancer cell lines in vitro and in human prostate tumors in vivo. The in-
duction of the senescence-associated secretory phenotype by androgen depletion was mediated, at least in part,
by down-regulation of S-phase kinase-associated protein 2, whereas the neuroendocrine differentiation of prostate
cancer cells was under separate control. These data demonstrate a previously unrecognized link between in-
hibition of androgen receptor signaling, down-regulation of S-phase kinase-associated protein 2, and the appear-
ance of secretory, tumor-promoting senescent cells in prostate tumors. We propose that ADT may contribute to
the development of androgen-independent prostate cancer through modulation of the tissue microenvironment
by senescent cells.
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Introduction
Androgen deprivation therapy (ADT) is an important treatment for
advanced stage prostate cancer and is achieved by androgen receptor
(AR) blockade and/or medical or surgical castration [1,2]. Although
ADT is initially very effective, treated tumors inevitably progress to
androgen-independent prostate cancer (AIPC), which is currently in-
curable and fatal. The mechanism through which ADT causes andro-
gen independence is therefore of considerable clinical importance.
One possible mechanism for the development of AIPC is modu-
lation of the tissue microenvironment by neuroendocrine (NE)-like
cancer cells, which emerge after ADT [3,4]. NE-like cancer cells are
capable of regulating the proliferation, invasion, and secretory activity
of surrounding cells through a paracrine mechanism involving a range
of secreted neuropeptides and cytokines (e.g., gastrin-releasing pep-
tide, serotonin, interleukin-8 (IL-8) [5]). The impact of the micro-
environment on prostate cancer progression may be further enhanced
by tumor heterogeneity characterized by the presence of multiple foci of
proliferative inflammatory atrophy, high-grade prostatic intraepithelial
neoplasia, and carcinoma in the peripheral zone of prostate [6].
Activation of AR signaling by a variety of growth factors and cyto-
kines, such as insulin-like growth factor 1, keratinocyte growth factor,
epidermal growth factor [7], IL-6 [8], or IL-8 [9], may also contribute
to development of AIPC [10]. Significantly, these factors may also be
secreted by senescent epithelial cells [11]. Senescence is a general cell
biologic phenomenon that limits the life span of cells and prevents un-
limited cell proliferation. Although senescent cells do not proliferate,
they are resistant to apoptosis and remain metabolically active [12].
Irreversible cell cycle arrest, the hallmark of senescence, can be triggered
by a variety of stimuli including deregulated expression of some onco-
genes [13,14] or tumor suppressors [15,16], telomere shortening [17],
oxidative stress [18], and chemotherapeutic drugs [19,20]. For these
reasons, induction of senescence is a potent defense against tumori-
genesis. There is a dark side to this defense mechanism, however:
metabolically active senescent cells may promote tumorigenicity of
neighboring malignant cells through the secretion of a range of growth
factors and cytokines [11,21,22]. Aged fibroblasts with this senescence-
associated secretory phenotype (SASP) are not the only cells capable
of modulating the prostate microenvironment and promoting carcino-
genesis [23]; senescent prostate epithelial cells can also behave in this
manner [24].
Senescence can be induced by a variety of signaling pathways, such
as p53-p21Cip1/Waf, p19Arf-p53, and p16INK4a-RB [25], which may
interact with one another or act independently to arrest cell prolifera-
tion [12]. Recently, S-phase kinase-associated protein 2 (Skp2) was
shown to play an important role in the promotion of senescence by
oncogenic Ras or by inactivation of PTEN [26]. Skp2, a crucial com-
ponent of the Skp, Cullin, F-box–containing complex, is an E3 ligase
involved in cell cycle progression through degradation of p27Kip1 and
other targets [27]. Elevation of Skp2 occurs in a variety of cancers,
including prostate [28,29]. Interestingly, Skp2 is regulated by AR sig-
naling, and inhibition of AR leads to down-regulation of Skp2 and
decreased cell proliferation [30,31].
Here we show that ADT induces senescence and neuroendocrine
differentiation (NED) of prostate cancer cells. Our results reveal a
previously unsuspected relationship between the inhibition of AR sig-
naling, down-regulation of Skp2, and the appearance of highly meta-
bolically active tumor-promoting senescent cells in prostate cancer
tissue. We propose that this mechanism plays a significant contribution
to prostate tumor progression.
Materials and Methods
Cell Cultures and Androgen Depletion
LNCaP cells (human prostate carcinoma cells; DSMZ, Braunschweig,
Germany) were cultivated in phenol red–free RPMI 1640 media
(Invitrogen, Carlsbad, CA) supplemented with NaHCO3 (Sigma
Aldrich, St Louis, MO), penicillin/streptomycin, and 5% fetal bovine
serum (FBS; both PAA, Pasching, Austria). For androgen depletion
studies, LNCaP cells were cultivated in 5% dextran/charcoal-stripped
FBS (CS). LAPC-4 cells (xenograft-derived human prostate carci-
noma cells [32]) were cultivated in Iscove modified Dulbecco medium
(Invitrogen) supplemented with NaHCO3, penicillin/streptomycin,
10% FBS, and 1 nM R1881 (PerkinElmer, Waltham, MA). For andro-
gen depletion studies, cells were cultivated in Iscove modified Dulbecco
medium with 10% CS. All cells were grown in a humidified incubator
(37°C, 5% CO2).
Androgen-Depleted Cell Growth Conditions
For the induction of senescence and NED, the cells were seeded
in appropriate growth medium with FBS, grown for 24 hours, and
at day 0, the growth medium was replaced with growth medium
supplemented with either complete FBS or CS. Cells were cultivated
without reseeding for 2 to 16 days, medium was changed twice a
week, and cells were harvested on days 2, 4, 8, and 16.
Western Blot Analysis of Cell Extracts
Protein extract preparation, gel electrophoresis, and Western blot
analysis were performed as previously described [33] using antibodies
described in Supplementary Materials and Methods. α-Tubulin or
β-actin was used as loading controls. Signal densities were analyzed
using ImageJ software (National Institutes of Health, Bethesda, MD)
and normalized to the appropriate loading control.
Detection of Telomerase Activity
Telomerase activity was detected using TRAPeze XL Telomerase
Detection Kit (Millipore, Billerica, MA) according to the manufac-
turer’s recommendation.
Immunofluorescence and Confocal Microscopy
Cells were fixed and stained with appropriate antibodies as de-
scribed in Supplementary Materials and Methods, and nuclei were
visualized by counterstaining with TOPRO-3 (Invitrogen) or DAPI
(4′, 6-diamidino-2-phenylindole; AppliChem, Darmstadt, Germany).
Fluorescent-stained samples were mounted in Mowiol 4-88/DABCO
(Calbiochem, Merck, Darmstadt, Germany) and viewed on a LSM
Leica SP5 (LeicaMicrosystems,Wetzlar, Germany) confocalmicroscope.
Flow Cytometry and Detection of Intracellular Antigens
Trypsinized cells were fixed in 2% paraformaldehyde at 4°C, permea-
bilized, and incubated with appropriate antibodies (described in Sup-
plementary Materials and Methods) diluted in PBS with 300 μg/ml
digitonin. Stained cells were analyzed on a FACSCalibur or FACS Aria
II Sorp (Becton Dickinson, San Jose, CA) cell sorter, and flow cytome-
try data were analyzed using FlowJo software (TreeStar, Ashland, OR).
The median fluorescence index (MFI) was calculated as the ratio of
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the median of fluorescence of the specific antibody and the median of
fluorescence of the isotype control.
Senescence-Associated β-Galactosidase Analysis
Senescence-associated β-galactosidase (SA-β-gal) cytochemistry was
performed at pH 6.0 using X-gal substrate (5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside; Pierce, Rockford, IL) as previously described
[34] and photographed using an Olympus IX-71 microscope (Olympus
Europe, Hamburg, Germany). SA-β-gal activity was quantified using
the fluorescent substrate 4-methylumbelliferyl-β-D-galactopyranoside
(AppliChem) as described previously [35], with minor modifications.
Fluorescence intensity was measured using a BMG FLUOStar Galaxy
(BMG LABTECH, Offenburg, Germany) plate reader and normalized
to the mean fluorescence intensity of the cells grown for 2 days in FBS.
Detection of Cathepsin B by Enzyme-Linked
Immunosorbent Assay
Cathepsin B levels in medium conditioned by either LNCaP or
LAPC-4 cells (see Supplementary Materials and Methods) were quan-
tified using the human Cathepsin B DuoSet Enzyme-Linked Immuno-
sorbent Assay (ELISA)Kit (DY2176; R&DSystems,Minneapolis,MN),
according to the manufacturer’s recommendations.
Cell Transfection and RNA Interference
DNA transfections were performed using Xfect transfection reagent
(Clontech, Mountain View, CA). Briefly, cells were exposed to 5 μg
of Skp2 mammalian expression vector (a kind gift from Keiichi I.
Nakayama, Kyushu University, Japan) in antibiotic-free Dulbecco
modified Eagle medium (DMEM) supplemented with 10% FBS for
4 hours, followed by 72 hours in DMEM supplemented with either
FBS or CS. For RNA interference studies, cells were incubated for
4 hours in Opti-MEM medium (Invitrogen), followed by transfection
with 10- to 40-nM small interfering RNA (siRNA) duplexes (Santa Cruz
Biotechnology, Santa Cruz, CA) directed against PTEN (sc-44272), Skp2
(sc-36499), or nontargeted control (sc-37007) using X-treme transfection
reagent (Roche, Bazel, Switzerland), according to the manufacturer’s rec-
ommendations. Cells were harvested 48 hours after transfection.
Immunostaining of Human Prostate Cancer Cells
Formalin-fixed, paraffin-embedded human prostate tumor samples
were obtained from an archive collected between 1998 and 2003
(Table W1). Samples were either fine-needle biopsies (preneoadjuvant
ADT) or prostatectomies (postneoadjuvant ADT), and all patients
were without distant metastases. Untreated control tumors (fine nee-
dle biopsies) were randomly selected. Samples were immunostained
with appropriate antibodies (described in Supplementary Materials
and Methods) using routine methods. Specimens were assessed semi-
quantitatively by histoscore (percentage of positivity in the area of
interest multiplied by staining intensity categorized as follows: 0,
absent; 1, weak; 2, moderate; and 3, strong).
Statistical Analysis
Statistical analysis was performed using STATISTICA for Windows
(StatSoft, Prague, Czech Republic) using one-way analysis of vari-
ance followed by the Tukey range test. If the data variances were non-
homogeneous, Kruskal-Wallis one-way analysis was performed.
Results
Long-term Androgen Depletion Induces Senescence in
Prostate Cancer Cells
Long-term androgen depletion induces cell cycle arrest without
apoptosis in LNCaP and LAPC-4 prostate cancer cells (data not
shown). In many cell types, irreversible cell cycle arrest correlates with
senescence. We used senescence-associated β-galactosidase (SA-β-gal)
activity, a general marker of senescence, to examine whether LNCaP
and LAPC-4 cells became senescent after androgen depletion; hydrogen
peroxide–treated human foreskin fibroblast (HFF-1) cells were used
as a positive control (Figure W1A). Using a cytochemical reaction,
many LNCaP cells were strongly positive for SA-β-gal after 16 days
growth without androgens (Figure 1A). Quantification of SA-β-gal
reactivity using a fluorescent substrate showed that androgen deple-
tion led to a statistically significant increase in SA-β-gal activity in both
LNCaP and LAPC-4 cells compared with control cells cultivated in
the presence of androgens (Figure 1B). We observed differences in
the kinetics of senescence induction in LNCaP and LAPC-4 cells.
These differences were in correlation with the sensitivity of a particular
cell line to the androgen deprivation and cell cycle arrest induction (data
not shown). LNCaP cells were more sensitive to androgen deprivation
in terms of inhibition of proliferation and showed a significant increase
in SA-β-gal level at day 4 of cultivation in CS; however, more tumori-
genic LAPC-4 cells were more resistant to the cell cycle arrest induction
in the androgen-deprived condition and showed a significant increase
in SA-β-gal level at day 8 of cultivation in CS.
To firmly establish the senescent phenotype of prostate cancer cells
after ADT, we examined nuclear markers of senescence. Using TRAP
(telomere repeat amplification protocol) to assay the telomerase activ-
ity, which is downregulated in senescent cells [36], we found that telo-
merase activity was almost undetectable in LNCaP cells after 8 days
of cultivation without androgens relative to control cells grown in
complete FBS (Figure 1C ). Using immunostaining, we examined
two chromatin markers of senescence: phosphorylated histone H2AX
(S139) and heterochromatin protein 1β (HP1β), a component of hetero-
chromatin foci, which were both significantly increased in senescent
HFF-1 (Figure W1B). Both HP1β-positive heterochromatin foci and
phospho-H2AX staining were increased by growth in androgen-depleted
media, consistent with these cells becoming senescent (Figure 1D).
Although phospho-H2AX staining was also increased by cultivation
for 16 days in the presence of androgens, the effect of androgen deple-
tion was evident as early as day 2. Taken together, these data indicate
that androgen depletion induced senescence in cultured prostate cancer
cell lines.
Androgen Depletion Induces a SASP in Prostate Cancer Cells
Recent findings have shown that senescent tumor cells are capable
of promoting tumorigenesis through their secretion of growth factors
and cytokines that have paracrine effects on nonsenescent neighboring
cells [11]. We looked for evidence of this SASP in our in vitro model
system by analyzing the expression of two components of the senes-
cence secretome [11]: insulin-like growth factor-binding protein 3
(IGFBP3) and cathepsin B. Using flow cytometry, we found that
IGFBP3 was significantly upregulated in prostate cancer cells culti-
vated for 8 days without androgens (Figure 2A). Using ELISA to
analyze the cell-conditioned medium, we found that cathepsin B secre-
tion from cells cultivated without androgens for 8 days was increased by
more than 100% relative to control cells (Figure 2B). NED, a frequent
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Figure 1. Androgen depletion induces senescence in prostate cancer cells. (A) Cytochemical detection of SA-β-gal activity in LNCaP cells
cultivated in presence (FBS) or absence (CS) of androgens for 2 or 16 days (2D, 16D). (B) Quantitative analysis of SA-β-gal activity in LNCaP
and LAPC-4 cells using fluorescent substrate. *Statistically significant changes (P < .05) compared with FBS-treated cells. (C) TRAP assay
to detect telomerase activity in LNCaP cells. (D) Immunofluorescent detection of HP1β and P-H2AX (S139) in LNCaP cells. White arrows and
arrowheads indicate P-H2AX (S139) staining and HP1β-positive foci, respectively.
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finding after ADT of human prostate cancer patients [4], was also
observed in our in vitro model system, based on increased levels of
the widely used NED markers γ-enolase and tubulin β-III (data not
shown). To determine whether functional NE-like cells were present
in our cultures, we used flow cytometry to analyze intracellular levels
of serotonin and histamine. Cells cultivated for 8 days under androgen-
depleted conditions expressed higher intracellular levels of both these
NE markers compared with cells cultivated in the presence of androgens
(Figure 2, C and D).
We next examined the reversibility of cell cycle arrest induced by an-
drogen depletion (Figure W2). After cultivating for 16 days in medium
with (FBS) or without (CS) androgens, LNCaP cells were reseeded at a
low density in the appropriate medium. When cells were cultivated in
FBS and reseeded in FBS, SA-β-gal reactivity was substantially reduced.
Figure 2. Analysis of markers of the senescent secretome and of NED after androgen depletion. (A) Flow cytometric analysis of IGFBP3 in
LNCaP and LAPC-4 cells cultivated for 8 days under the growth conditions indicated (see Materials and Methods). Histogram represents
typical result obtained by flow cytometric analysis. Error bars, MFI ± SD from two independent experiments. (B) Cathepsin B concentration,
determined by ELISA, in medium conditioned by LNCaP or LAPC-4 cells cultivated for 8 days with or without androgen. Error bars, mean ±
SD from four experiments. *Statistical significance (P < .05). (C) Flow cytometric analysis of serotonin in LNCaP and LAPC-4 cells and
(D) histamine in LAPC-4 cells cultivated for 8 days with or without androgen. Error bars, MFI ± SD from two independent experiments.
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In contrast, LNCaP cells grown in CS medium remained senescent and
nonproliferative even after reseeding at a low density and cultivating in
the presence of androgens (Figure W2, A-C , 16D CS + FBS). Induction
of NED after androgen depletion was also irreversible (data not shown).
In summary, these data show that long-term androgen depletion
in our in vitro model induced irreversible senescence and that this was
associated with increased expression of senescence-associated secretory
factors and markers of NED.
Androgen Depletion Induces Vimentin Expression in Prostate
Cancer Cells
To further investigate the phenotype of prostate cancer cells under-
going senescence and NED in response to androgen depletion, we
analyzed the expression of cytokeratin and vimentin, which are mark-
ers of epithelial cells and mesenchymal cells, respectively. Using a
pan-cytokeratin antibody, we found that androgen depletion, as
well as high cell density, upregulated the expression of several cyto-
keratins (Figure W3). We also found that vimentin was strongly in-
duced by androgen depletion (Figure 3A). Induction of a strongly
positive vimentin subpopulation was confirmed using flow cytometry
(Figure 3B) and confocal microscopy (Figure 3C ). Vimentin ex-
pression in epithelial cells may indicate an epithelial-to-mesenchymal
transition (EMT) [37]. To examine whether EMToccurred in our cul-
tures, we examined the expression of N-cadherin and E-cadherin,
which are upregulated and downregulated, respectively, during EMT
[38]. N-cadherin was not expressed by LNCaP cells either before or
after androgen depletion, and the expression of the epithelial marker
E-cadherin was not significantly downregulated after androgen with-
drawal (Figure 3A). These data indicate that the up-regulation of
vimentin after androgen depletion is unlikely to be due to EMT. Be-
cause vimentin is also expressed in senescent fibroblasts [39], it is possi-
ble that induction of vimentin in our model is indicative of senescence.
Figure 3. Androgen depletion induces expression of vimentin in LNCaP cells. (A) Western blot analysis of vimentin, E-cadherin, and
N-cadherin. (PC, positive control: whole-cell extract from mouse brain.) (B) Flow cytometric analysis showing the percentage of cells
expressing high levels of vimentin. Similar results were obtained from three independent experiments. (C) Immunocytochemical detec-
tion of vimentin in cultured cells.
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We wanted to know if induction of vimentin occurred in human
prostate tumors after ADT and examined expression of vimentin, as
well as the NED markers chromogranin A and γ-enolase, in samples
of human prostate cancers collected pre- and/or postneoadjuvant ADT
(Table W1). Before ADT, the expression of vimentin, chromogranin A,
and γ-enolase in epithelial cells of the prostate tumor samples was either
undetectable or at low levels (Figure 4,A and B, pre, epi). After ADT, the
expression of all three markers was significantly increased in epithelial
Figure 4. Up-regulation of vimentin and NED markers in human prostate cancer epithelial cells after neoadjuvant ADT. (A) Immunohisto-
chemical detection of γ-enolase, chromogranin A, and vimentin. Sample pairs are from the same individual preneoadjuvant and post-
neoadjuvant ADT. Expression of vimentin in epithelial and stromal cells is easily distinguishable at 40× magnification (inset). (B)
Quantification of γ-enolase, chromogranin A, and vimentin expression in patient tumor samples. *Statistical significance (P < .05) com-
pared with samples from patients before receiving ADT.
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Figure 5. Down-regulation of Skp2 by androgen depletion induced senescence in prostate cancer cells. (A) Western blot detection of Skp2
and PTEN expression in cells cultivated in the presence (FBS) or absence (CS) of androgens. (B) Western blot analysis of Skp2, p27Kip1, and
γ-enolase after overexpression of Skp2 in LAPC-4 cells. (C) Western blot analysis of Skp2, p27Kip1, and γ-enolase in LNCaP cells transfected
with control or Skp2-specific siRNA followed by incubation in FBS. (D) Western blot analysis of Skp2, p27Kip1, PTEN, and γ-enolase in LAPC-4
cells transfected with control, Skp2-, or PTEN-specific siRNA followed by incubation in presence (FBS) or absence (CS) of androgens for
48 hours. The bar graphs represent the average optical density (OD) ± SD. (E) Frequency of SA-β-gal–positive cells after transfection
with control or Skp2 specific siRNA followed by cultivation for 48 hours in the presence (FBS) or absence (CS) of androgens. A mini-
mum of 1000 cells was counted for each experimental group. *Statistical significance (P < .05) compared with the cells cultivated in FBS.
#Statistical significance (P < .05) compared with cells cultivated for 2 days in CS.
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cells in samples from the same individuals (Figure 4A, post), and their
scores were significantly higher (Figure 4B). In contrast, vimentin expres-
sion in stromal cells of the prostate was unaffected by ADT. These results
show that induction of senescence and NED is associated with
the expression of vimentin in epithelial prostate cancer cells.
Role of PTEN-Skp2 Signaling in the Induction of Senescence
by Androgen Depletion
PTEN-Skp2 signaling is a crucial regulator of p27Kip1 and senescence
[15,26,27]. In LNCaP and LAPC-4 cells grown without androgens,
Skp2 became downregulated, whereas the level of PTEN increased
over time (Figure 5A). LNCaP cells were PTEN null [33] and were
not assayed for PTEN. Because Skp2 expression can be controlled by
AR, and androgen depletion led to up-regulation of p27Kip1 in our model
(data not shown), we examined the role of PTEN and Skp2 in andro-
gen depletion–induced NED and senescence. Transient transfection of
LAPC-4 cells with the Skp2 expression vector [40] led to a slight de-
crease in p27Kip1 expression (Figure 5B), whereas partial depletion of
Skp2 using RNA interference was sufficient to upregulate p27Kip1 in
both LNCaP and LAPC-4 cells (Figure 5, C and D). Interestingly, al-
though depletion of Skp2 alone had no effect on the level of γ-enolase,
codepletion of Skp2 and PTEN with siRNA did cause γ-enolase to
decrease in LAPC-4 cells grown under normal or androgen-depleted
conditions (Figure 5D). Finally, down-regulation of Skp2 by transfection
with Skp2 siRNA was followed by a significant increase in the number
of SA-β-gal–positive cells in LNCaP cultures grown in the presence of
androgens, as well as in LAPC-4 cultures grown without androgens
(Figure 5E). These data show that down-regulation of Skp2 by androgen
depletion contributes to the induction of senescence in prostate cancer
cells and that Skp2 is not involved in NED.
Discussion
To our knowledge, this is the first demonstration that androgen de-
pletion induces senescence of prostate cancer cells paralleled with up-
regulation of vimentin expression. Senescence, a permanent cell cycle
arrest coupled with resistance to apoptosis and high metabolic activity,
is a potent defense against tumorigenesis. However, it is now becom-
ing clear that cells with a SASP may actually promote tumor progres-
sion through their secretion of factors that can significantly modulate
the tissue microenvironment [21,41,42]. Using a panel of markers to
identify senescent cells, including SA-β-gal activity, telomerase activity,
and formation of HP1β foci, we have found that androgen depletion
induced irreversible senescence in prostate cancer cells in vitro. We also
found that expression of both cathepsin B and IGFBP3, two markers
of SASP [11,43], was significantly increased after androgen depletion
and confirmed that androgen depletion promoted NED of prostate
cancer cells [44]. This is the first demonstration that androgen deple-
tion leads to senescence and NED of prostate cancer cells. Interest-
ingly, senescent and NE-like cells are associated with high metabolic
activity and the potential to influence the behavior of nonsenescent
neighboring cells.
To further characterize the phenotype of prostate cancer cells after
androgen depletion, we examined markers of epithelial and mesen-
chymal cells. Surprisingly, ADT increased the expression of the epithe-
lial marker cytokeratin and the mesenchymal marker vimentin [45].
Similar findings were observed in tumor samples from prostate cancer
patients after ADT, and these are the first demonstration that androgen
depletion upregulates vimentin in prostate cancer epithelial cells. More-
over, vimentin expression was paralleled with the expression of NED
markers γ-enolase and chromogranin A. Although vimentin is a well-
known marker of EMT [37], it is also expressed by senescent fibro-
blasts [39]. Because the expression of both N-cadherin and E-cadherin
was unaffected by androgen depletion, the NE-like cells in our cul-
tures were unlikely to be undergoing an EMT [38]. Instead, the robust
expression of vimentin after androgen depletion may be associated
with the induction of senescence in prostate cancer epithelial cells.
Skp2 was recently implicated in promoting oncogene-induced se-
nescence [26]. In the prostate, as well as in our system, inhibition
of AR is correlated with down-regulation of Skp2 and decreased pro-
liferation [30,31]. We addressed the causal relationship between these
findings and found that depletion of Skp2 using RNAi was sufficient
to induce senescence in LNCaP cells and also significantly potentiated
androgen depletion-induced senescence in LAPC-4 cells. These results
indicate that down-regulation of Skp2 is an important component of the
mechanism through which androgen depletion induces senescence in
prostate cancer cells. Although down-regulation of Skp2 was recently re-
ported to induce senescence in the context of PTEN inactivation [26],
Figure 5. (continued).
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our data clearly demonstrate that Skp2 inactivation is sufficient to
promote senescence even in the presence of elevated levels of PTEN. Pre-
sumably another mechanism, perhaps loss of heterozygosity of TP53,
is involved in Skp2-mediated induction of senescence in LAPC-4
cells [46].
Our findings demonstrate a novel linkage between the inhibition
of AR activity, down-regulation of Skp2, and the formation of secre-
tory, senescent cells in prostate tumors. These observations suggest
that modulation of the prostate tumor microenvironment after andro-
gen depletion is a major contributory factor in the development of
androgen-independent prostatic cancer, especially because several com-
ponents of the SASP secretome (e.g., IL-6, IL-8, KGH, and epidermal
growth factor) are capable of transactivating AR under androgen-
depleted conditions [7–9]. We speculate that, in prostate cancer pa-
tients undergoing ADT, paracrine factors released by senescent cells
override the requirement for androgen ligand and promote the clonal
expansion of androgen-independent cells, leading to failure of ADT
and progression of the disease to androgen independence.
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Supplementary Materials and Methods
Induction of Senescence in Human Foreskin Fibroblast Cell
Line HFF-1 with Hydrogen Peroxide
Human foreskin fibroblast HFF-1 cells (ATCC, LGC Standards Sp.
z.o.o., Lomianki, Poland) were cultivated in DMEM (Sigma) supple-
mented with 15% FBS. Senescence was induced in HFF-1 cells as
described previously [1]. Cells were seeded at a density of 25,000/cm2
in complete media. After 24 hours, the medium was replaced, the cells
were treated with 200 μMH2O2 for 2 hours, and the medium was re-
placed by freshmediumwithoutH2O2. Treated cells were cultivated for
another 96 hours with one change of growth medium. After 96 hours,
the cells were reseeded at a density of 25,000/cm2 and allowed to re-
cover for 24 hours before the second treatment with 200 μM H2O2.
Treated cells were cultivated for an additional 6 to 7 days and then har-
vested for further analysis.
Cell Number Assessment
The cell numbers were determined using a Coulter Counter ZM
(Beckman Coulter, Brea, CA).
Experimental Design and Sample Collection for ELISA
For the collection of conditioned medium for ELISA analysis, the
cells were cultivated as described in the Materials and Methods for
2 or 8 days. The last medium exchange was performed 48 hours before
medium collection. Cellular debris was removed from conditioned
medium by centrifugation (500g, 10 minutes), and the supernatant
was stored at −80°C. Cathepsin B detection was performed according
to the manufacturer’s recommendation. The absorbance values were
normalized to cell number.
Antibodies for Western Blot Analysis
Primary antibodies against human γ-enolase (sc-21738) and PTEN
(sc-7974) were obtained from Santa Cruz Biotechnology; cytokeratin
(CK) 7 + 17 (11-109-C100), CK 8 (11-104-C100), CK 18 (11-106-
C100), and pan-reactive CK (11-108-C100) antibodies were from
Exbio, Prague, Czech Republic; p27Kip1 (610242), E-cadherin (610182),
andN-cadherin (610920) antibodies were fromBDPharmingen, San Jose,
CA; vimentin (V6389), β-actin (A5441), and α-tubulin (T9026) anti-
bodies were from Sigma; Skp2 (no. 313) was from Cell Signaling Tech-
nology, Danvers, MA; horseradish peroxidase–conjugated antimouse IgG
(no. NA931) and antirabbit IgG (no. NA934) were from GE Healthcare,
Chalfont St Giles, United Kingdom.
Antibodies for Flow Cytometric Detection
The following primary antibodies were used: vimentin (V6389),
serotonin (S5545), histamine (H7403), and IGFBP3 (HPA013357,
all from Sigma). Afterward, the cells were washed and incubated
with the appropriate secondary antibody conjugated with Alexa
Fluor 488 (Invitrogen). Far red LIVE/DEAD Fixable Dead Cell Stain
Kit (Invitrogen) was used for the exclusion of dead cells.
Antibodies for Immunofluorescence and Confocal Microscopy
For the detection of HP1β (07-333; Upstate), phospho-H2AX
(Ser 139, 05-636; Upstate, Millipore, Billerica, MA) and vimentin
(V6389), the cells were fixed with 4% paraformaldehyde, permeabilized
with 0.1% Triton X-100 and 0.1% saponin, blocked with 1% bovine
serum albumin, washed, and incubated with primary antibody over-
night at 4°C [2]. The samples were then incubated with the appropriate
secondary antibody conjugated with Alexa Fluor 488 or Alexa Fluor 594
(Invitrogen).
Antibodies for Immunocytochemistry
The following antibodies were used: γ-enolase (anti-NSE, clone BBS/
NC/VI-H14; Serotec,Kidlington,UnitedKingdom), vimentin (V9;Dako,
Glostrup, Denmark), chromogranin A antibody (LK2H10; Serotec),
and secondary antibody (Dual Link; Dako).
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Table W1. Characteristics of Human Prostate Tumor Samples.
Patient No. Age at dg (yr) PSA at dg Neoadjuvant Therapy Tissue pT pN GS
1 55 83.5 HFM Both pT3b pN0 5 + 3
2 68 108.4 BIC Both pT3b pN1 3 + 4
3 54 60 HFM, LHRH Both pT4 pN0 3 + 3
4 60 9.7 BIC, HFM, LHRH Both pT2b pN0 3 + 4
5 64 52 HFM After pT3a pN1 4 + 5
6 58 29.1 HFM After pT2b pN0 3 + 4
7 50 47.2 HFM After pT3b pN1 4 + 5
8 54 24.39 HFM, CPA After pT3b pN0 4 + 5
9 66 8.2 HFM After pT2b pN0 3 + 5
10 63 5.7 BIC, HFM After pT2b pN0 3 + 4
11 59 8.5 None Before pT2b pNx 3 + 4
12 66 7.07 None Before pT2b pN0 4 + 4
13 69 8.22 None Before pT3a pN0 2 + 2
14 63 9.8 None Before pT2c pNx 3 + 4
15 66 32 None Before pT2b pN0 3 + 2
16 66 8.29 None Before pT2b pN0 4 + 5
BIC indicates bicalutamide; CPA, cyproterone acetate; dg, diagnosis; GS,Gleason score; HFM, hydro-
xyflutamide; LHRH, luteinizing hormone-releasing hormone analog; pNx, no lymphadenectomy;
pT, pathologic Tstage; Tissue, type of tissue available with respect to the neoadjuvant therapy (before,
after, both).
Figure W1. Expression of markers of senescence in human foreskin fibroblasts (HFF-1) cells after exposure to 200 μM hydrogen peroxide
(H2O2). (A) SA-β-gal staining of control and H2O2-treated HFF-1 cells. (B) Confocal images of P-H2AX (S139) and HP1β immunofluorescence
in control and H2O2-treated HFF-1 cells. White arrow and arrowhead, positive signal for P-H2AX (S139) staining and formation of HP1β
foci, respectively.
Figure W2. Senescence induced by androgen depletion is irreversible. (A) Cytochemical detection of SA-β-gal activity in long-term culti-
vated LNCaP cells after reseeding. Cytochemical analysis of SA-β-gal activity showed false positivity in the case of highly confluent cells,
when such cells were negative after their dissociation followed by cytospin. (B) The cells were cultivated for 16 days and then reseeded
at a low density (10,000 cells/cm2) in appropriate media. The cells grown in FBS were reseeded in medium with FBS; cells grown in CS
were reseeded in medium containing either CS or FBS. Reseeded cells were grown for an additional 2, 4, and 8 days (16 + 2, 16 + 4, and
16 + 8, respectively) without reseeding. (C) Analysis of cell numbers in response to reseeding. Data represent mean ± SD of two indepen-
dent experiments.
Figure W2. (continued).
Figure W3. Western blot analysis of expression of cytokeratins in LNCaP and LAPC-4 cells cultivated in the presence (FBS) or absence
(CS) of androgens. (A) Expression of cytokeratins detected by a pan-reactive cytokeratin antibody. (B) Cytokeratin 7 + 17, cytokeratin 8,
and cytokeratin 18 expression in LNCaP cells. α-Tubulin was used as a loading control.
